Core Viewpoint - The company expects a net profit of 25 million to 35 million yuan for the fiscal year 2025, representing a year-on-year decline of 67.66% to 76.90% due to increased competition and a decrease in sales revenue in its core sexual health business [1] Group 1: Financial Performance - The projected net profit for 2025 is between 25 million and 35 million yuan [1] - This represents a significant decline of 67.66% to 76.90% compared to the previous year [1] Group 2: Business Operations - The sexual health business has experienced a decline in sales revenue due to the increasing number of competitors and intense market competition [1] - However, there are signs of a gradual recovery in market demand [1] Group 3: Product Strategy - The company plans to strengthen brand promotion efforts for its product "Aiting Jiu" (Dapoxetine Hydrochloride Tablets) to boost sales [1] - The upcoming launch of the new product "Aiting Lie" (Finasteride and Tadalafil Capsules) is expected to contribute to growth in the sexual health segment moving forward [1]
泰恩康：预计2025年净利润同比下降67.66%-76.90%